The dramatic approval of Lorcaserin, now known by the trade name Belviq, was announced on June 27, 2012. Lorcaserin, CAS# 846589-98-8, is the first drug to be approved for weight loss in over twelve years. This announcement, made by representatives from both Easai and Arena Pharmaceuticals was a welcome one for researchers, patients and practitioners[…]
Intended for weight management, including weight loss and maintenance of weight loss, lorcaserin is poised to become the next weight loss drug. Lorcaserin is aimed at clinically obese patients, or patients with a Body Mass Index, or BMI, >30, or patients who are overweight (BMI >27) and have at least one weight related co-morbid condition.[…]
LGM Pharma supplies Topiramate, Bupropion, Naltrexone and Lorcaserin – Active Pharmaceutical Ingredients (APIs) used to treat obesity.